GlassScriptPhysician profile
Junaid H Memon
NPI 1932143666
$3,835.12
in general payments reported to CMS, 2019-2025
17 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $509 · 2021: $1,079 · 2022: $694 · 2023: $478 · 2024: $494 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,610.40 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $949.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $375.15 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $186.72 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $163.72 | 2021-2022 | |
| Pfizer INC. | $143.53 | 2019-2025 | |
| Astellas Pharma US INC | $134.81 | 2020-2021 | |
| Lilly USA, LLC | $63.06 | 2019-2025 | Jardiance |
| Dexcom, INC. | $61.42 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $32.43 | 2022-2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $19.32 | 2024 | Gemtesa |
| Scynexis, INC. | $19.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.45 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.12 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $13.73 | 2021 | |
| Amgen INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.